Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 100

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 100
---
 complete and
accurate. In that regard, Leerink Partners was advised by Aadi, and Leerink Partners assumed, at Aadi’s direction, that the Internal Data (including, without limitation, the Aadi Projections) were reasonably prepared on bases reflecting the
best currently available estimates and judgments of the management of Aadi as to the matters covered thereby and Leerink Partners relied, at Aadi’s direction, on the Internal Data for purposes of its analysis and its opinion. Leerink Partners
expressed no view or opinion as to the Internal Data (including, without limitation, the Aadi Projections) or the assumptions on which the Internal Data was based. In addition, at Aadi’s direction, Leerink Partners did not make any independent
evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Aadi, Aadi Sub or Kaken, nor was Leerink Partners furnished with any such evaluation or
appraisal, and Leerink Partners was not asked to conduct, and did not conduct, a physical inspection of the properties or assets of Aadi, Aadi Sub or Kaken.

Leerink Partners assumed, at Aadi’s direction, that the final executed Divestiture Agreement would not differ in any respect material to
Leerink Partners’ analysis or its opinion from the last version of the Divestiture Agreement reviewed by Leerink Partners. Furthermore, Leerink Partners assumed, at Aadi’s direction, that the Divestiture would be consummated on the terms
set forth in the Divestiture Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be
material to Leerink Partners’ analysis or its opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Divestiture, as applicable, no delay, limitation,
restriction, condition or other change would be imposed, the effect of which would be material to Leerink Partners’ analysis or its opinion, and that each of Aadi, Aadi Sub and Kaken would perform their respective covenants and agreements set
forth in the Divestiture Agreement in accordance with the terms of the Divestiture Agreement. Leerink Partners did not evaluate and did not express any opinion as to the solvency or fair value of Aadi, Aadi Sub or